ADVERTISEMENT

Gland Pharma Q2 Review - Beat Due To Controlled Costs; Base Business Yet To Witness Revival: Motilal Oswal

With two years of earnings decline in FY23/FY24, the brokerage believes the earnings are largely at trough and expected to experience revival over FY25-27.

<div class="paragraphs"><p>Injectables manufactured by Gland Pharma Ltd. (Source: Company website).</p></div>
Injectables manufactured by Gland Pharma Ltd. (Source: Company website).
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More